Vivoryon Therapeutics N.V. Announces Late-breaking Oral Presentation at the American Society of Nephrology Kidney Week 2024
Vivoryon Therapeutics (Euronext Amsterdam: VVY) announced that its abstract on Varoglutamstat has been selected for a late-breaking oral presentation at the American Society of Nephrology (ASN) Kidney Week 2024 in San Diego, California, from October 23 to 27. The abstract titled 'Varoglutamstat Increases Glomerular Filtration in Elderly Patients without Signs of Proteinuria and Potentially Offers a New Approach to Treat Diabetic Kidney Disease (DKD)' will be presented by Frank Weber, M.D., CEO, on October 25, 2024, at 5:40 PM PDT.
Varoglutamstat (PQ912) is a potent and selective inhibitor of human glutaminyl cyclases QPCT and QPCTL, with potential therapeutic applications in inflammatory and fibrotic diseases, neurodegenerative diseases, and cancer. Initially developed for Alzheimer's disease (AD), it has shown favorable safety and tolerability in various clinical studies. The Phase 2 VIVIAD study in AD included the investigation of kidney function to explore the role of QPCT/L inhibition on kidney function.
Vivoryon Therapeutics (Euronext Amsterdam: VVY) ha annunciato che il suo abstract su Varoglutamstat è stato selezionato per una presentazione orale dell'ultima ora durante la American Society of Nephrology (ASN) Kidney Week 2024 a San Diego, California, dal 23 al 27 ottobre. L'abstract intitolato 'Varoglutamstat Aumenta la Filtrazione Glomerulare nei Pazienti Anziani Senza Segni di Proteinuria e Potenzialmente Offre un Nuovo Approccio per Trattare la Malattia Renale Diabetica (DKD)' sarà presentato da Frank Weber, M.D., CEO, il 25 ottobre 2024 alle 17:40 PDT.
Varoglutamstat (PQ912) è un inibitore potente e selettivo delle ciclossidasi umane QPCT e QPCTL, con potenziali applicazioni terapeutiche in malattie infiammatorie e fibrotiche, malattie neurodegenerative e tumori. Inizialmente sviluppato per la malattia di Alzheimer (AD), ha mostrato un favorevole profilo di sicurezza e tollerabilità in vari studi clinici. Lo studio di Fase 2 VIVIAD in AD ha incluso l'indagine sulla funzione renale per esplorare il ruolo dell'inibizione di QPCT/L sulla funzione renale.
Vivoryon Therapeutics (Euronext Ámsterdam: VVY) anunció que su resumen sobre Varoglutamstat ha sido seleccionado para una presentación oral de última hora en la American Society of Nephrology (ASN) Kidney Week 2024 en San Diego, California, del 23 al 27 de octubre. El resumen titulado 'Varoglutamstat Aumenta la Filtración Glomerular en Pacientes Mayores Sin Signos de Proteinuria y Ofrece Potencialmente un Nuevo Enfoque para Tratar la Enfermedad Renal Diabética (DKD)' será presentado por Frank Weber, M.D., CEO, el 25 de octubre de 2024 a las 5:40 PM PDT.
Varoglutamstat (PQ912) es un potente y selectivo inhibidor de las ciclasas glutaminil humanas QPCT y QPCTL, con aplicaciones terapéuticas potenciales en enfermedades inflamatorias y fibrosas, enfermedades neurodegenerativas y cáncer. Inicialmente desarrollado para la enfermedad de Alzheimer (AD), ha mostrado un perfil de seguridad y tolerabilidad favorable en varios estudios clínicos. El estudio de Fase 2 VIVIAD en AD incluyó la investigación de la función renal para explorar el papel de la inhibición de QPCT/L en la función renal.
Vivoryon Therapeutics (유로넥스트 암스테르담: VVY)는 Varoglutamstat에 대한 초록이 캘리포니아 샌디에이고에서 2024년 10월 23일부터 27일까지 열리는 미국신장학회(ASN) 신장 주간 2024에서 긴급 발표로 선정되었음을 발표했습니다. 'Varoglutamstat이 단백뇨 증상이 없는 노인 환자의 사구체 여과율을 증가시키고 당뇨병성 신장질환(DKD) 치료를 위한 새로운 접근 방식을 제공할 수 있다'라는 제목의 초록은 Frank Weber, M.D., CEO에 의해 2024년 10월 25일 오후 5시 40분 PDT에 발표될 예정입니다.
Varoglutamstat (PQ912)는 인체의 glutaminyl cyclases QPCT 및 QPCTL의 강력하고 선택적인 억제제로, 염증 및 섬유화 질환, 신경퇴행성 질환 및 암에 대한 잠재적인 치료 응용이 있습니다. 알츠하이머병(AD)을 위해 처음 개발되었으며, 여러 임상 연구에서 안전성과 내약성에 대한 긍정적인 결과를 보였습니다. AD에 대한 2상 VIVIAD 연구에서는 신장 기능을 조사하여 QPCT/L 억제가 신장 기능에 미치는 역할을 탐구했습니다.
Vivoryon Therapeutics (Euronext Amsterdam: VVY) a annoncé que son résumé sur Varoglutamstat a été sélectionné pour une présentation orale de dernière minute lors de la American Society of Nephrology (ASN) Kidney Week 2024 à San Diego, Californie, du 23 au 27 octobre. Le résumé intitulé 'Varoglutamstat Augmente la Filtration Glomérulaire chez les Patients Âgés Sans Signes de Protéinurie et Offre Potentiellement Une Nouvelle Approche pour Traiter la Maladie Rénale Diabétique (DKD)' sera présenté par Frank Weber, M.D., CEO, le 25 octobre 2024 à 17h40 PDT.
Varoglutamstat (PQ912) est un inhibiteur puissant et sélectif des cyclases glutaminyles humaines QPCT et QPCTL, avec des applications thérapeutiques potentielles dans les maladies inflammatoires et fibrotiques, les maladies neurodégénératives et le cancer. Initialement développé pour la maladie d'Alzheimer (AD), il a montré un profil de sécurité et de tolérabilité favorable dans diverses études cliniques. L'étude de Phase 2 VIVIAD dans l'AD a inclus l'investigation de la fonction rénale pour explorer le rôle de l'inhibition de QPCT/L sur la fonction rénale.
Vivoryon Therapeutics (Euronext Amsterdam: VVY) gab bekannt, dass ihr Abstract über Varoglutamstat für eine Spontanpräsentation bei der American Society of Nephrology (ASN) Kidney Week 2024 in San Diego, Kalifornien, vom 23. bis 27. Oktober ausgewählt wurde. Der Abstract mit dem Titel 'Varoglutamstat Erhöht die Glomeruläre Filtration bei Älteren Patienten ohne Anzeichen von Proteinurie und Bietet Potenziell Einen Neuen Ansatz zur Behandlung der Diabetischen Nierenerkrankung (DKD)' wird von Frank Weber, M.D., CEO am 25. Oktober 2024 um 17:40 Uhr PDT präsentiert.
Varoglutamstat (PQ912) ist ein potenter und selektiver Inhibitor der menschlichen Glutaminyl-Cyclasen QPCT und QPCTL, mit potenziellen therapeutischen Anwendungen bei entzündlichen und fibrotischen Erkrankungen, neurodegenerativen Erkrankungen und Krebs. Ursprünglich für die Alzheimer-Krankheit (AD) entwickelt, hat es in verschiedenen klinischen Studien ein günstiges Sicherheits- und Verträglichkeitsprofil gezeigt. Die Phase-2-Studie VIVIAD bei AD umfasste die Untersuchung der Nierenfunktion, um die Rolle der Hemmung von QPCT/L auf die Nierenfunktion zu erkunden.
- Vivoryon's abstract on Varoglutamstat was selected for a late-breaking oral presentation at ASN Kidney Week 2024.
- Varoglutamstat demonstrated an increase in glomerular filtration in elderly patients without signs of proteinuria.
- The VIVIAD study in AD patients was not primarily focused on kidney function, which may limit the generalizability of the findings regarding kidney disease.
Halle (Saale) / Munich, Germany, October 11, 2024 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on the discovery and development of small molecule medicines to modulate the activity and stability of pathologically altered proteins, today announced that the Company’s abstract “Varoglutamstat Increases Glomerular Filtration in Elderly Patients without Signs of Proteinuria and Potentially Offers a New Approach to Treat Diabetic Kidney Disease (DKD)” has been selected for a late-breaking oral presentation at the American Society of Nephrology (ASN) Kidney Week 2024 in San Diego, California, held October 23 to 27.
“We are truly excited that our abstract has been selected for a late-breaking oral presentation at the ASN Kidney Week 2024,” said Frank Weber, M.D., CEO of Vivoryon. “We are very much looking forward to sharing our results with the scientific and medical experts in the kidney field.”
ASN Kidney Week 2024 Presentation Details:
| Title: | Varoglutamstat Increases Glomerular Filtration in Elderly Patients without Signs of Proteinuria and Potentially Offers a New Approach to Treat Diabetic Kidney Disease (DKD) |
| Presenting Author: | Frank Weber, M.D., CEO, Vivoryon |
| Abstract #: | FR-OR113 |
| Session Title: | Late-Breaking Science Orals - 1 |
| Location: | Room 6C (Convention Center) |
| Date/Time: | October 25, 2024, 5:40 PM to 5:50 PM (PDT) |
###
Varoglutamstat in Kidney Disease
Varoglutamstat (PQ912) is a proprietary, potent and selective inhibitor of human glutaminyl cyclases QPCT and QPCTL with therapeutic potential in indications including inflammatory and fibrotic diseases, neurodegenerative diseases, cancer and others. Initially advancing development aiming to treat Alzheimer’s disease (AD), varoglutamstat has been investigated in a number of different clinical studies, all of which have consistently demonstrated a favorable safety and tolerability profile both in healthy volunteers and patients with AD. Based on the known anti-inflammatory activity of varoglutamstat, the protocol for the Phase 2 VIVIAD study in AD, which was completed in the first half of 2024, included the investigation of kidney function and measurement of biomarkers of kidney inflammation and fibrosis to explore the role of QPCT/L inhibition on kidney function. Although patients in VIVIAD were selected for their AD status and not for their kidney function level, many of them have reduced kidney function due to age and/or comorbidities.
About Vivoryon Therapeutics N.V.
Vivoryon is a clinical stage biotechnology company focused on developing innovative small molecule-based medicines. Driven by its passion for ground-breaking science and innovation, the Company strives to change the lives of patients in need suffering from severe diseases. The Company leverages its in-depth expertise in understanding post-translational modifications to develop medicines that modulate the activity and stability of proteins which are altered in disease settings. The Company has established a pipeline of orally available small molecule inhibitors for various indications including Alzheimer’s disease, inflammatory and fibrotic disorders, including of the kidney, and cancer. www.vivoryon.com.
Vivoryon Forward Looking Statements
This press release includes forward-looking statements, including, without limitation, those regarding the business strategy, management plans and objectives for future operations of Vivoryon Therapeutics N.V. (the “Company”), estimates and projections with respect to the market for the Company’s products and forecasts and statements as to when the Company’s products may be available. Words such as “anticipate,” “believe,” “estimate,” “expect,” “forecast,” “intend,” “may,” “plan,” “project,” “predict,” “should” and “will” and similar expressions as they relate to the Company are intended to identify such forward-looking statements. These forward-looking statements are not guarantees of future performance; rather they are based on the Management’s current expectations and assumptions about future events and trends, the economy and other future conditions. The forward-looking statements involve a number of known and unknown risks and uncertainties. These risks and uncertainties and other factors could materially adversely affect the outcome and financial effects of the plans and events described herein. The Company’s results of operations, cash needs, financial condition, liquidity, prospects, future transactions, strategies or events may differ materially from those expressed or implied in such forward-looking statements and from expectations. As a result, no undue reliance should be placed on such forward-looking statements. This press release does not contain risk factors. Certain risk factors that may affect the Company’s future financial results are discussed in the published annual financial statements of the Company. This press release, including any forward-looking statements, speaks only as of the date of this press release. The Company does not assume any obligation to update any information or forward-looking statements contained herein, save for any information required to be disclosed by law.
For more information, please contact:
Investor Contact
Vivoryon Therapeutics N.V.
Dr. Manuela Bader, Director IR & Communication
Email: IR@vivoryon.com
Media Contact
Trophic Communications
Stephanie May
Tel: +49 171 1855682
Email: vivoryon@trophic.eu
Attachment
FAQ
What is the main focus of Vivoryon Therapeutics' presentation at ASN Kidney Week 2024?
When and where will Vivoryon Therapeutics present their findings on Varoglutamstat?
What is Varoglutamstat and what are its potential therapeutic applications?
What were the results of the Phase 2 VIVIAD study in Alzheimer's disease (AD) patients?
What is the stock symbol for Vivoryon Therapeutics?
